2025+中国指南：结节性痒疹的诊断和治疗（英文版）

Correspondence to: Fei Hao, Department of Dermatology,Third Affiliated Hospital,

The Chongqing Medical University,Chongqing 400016,China E-Mail:haofei62@126.com;Xinghua Gao, Department of Dermatology,The First Hospital of China Medical University,155N Nanjing Street,Heping District,Shenyang,Liaoning 110001,China E-Mail:xhao@cmu.edu.cn

Copyright© 2025 The Chinese Medical Association, produced by Wolters Kluver, Inc. under the CC-BY-NC-ND license.This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0(CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited.The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2025;XX(XX)

Received: 17-02-2025; Online: 16-09-2025 Edited by: Lishao Guo

Chinese Medical Journal 2025;XX(XX)

www.cmj.org

guidance and reference for clinicians (Supplementary File, http://links.lw.com/CM9/C544). This guideline has been registered at the International Practice Guideline Registry Platform (http://www.guidelines-registry.org; No.PREPAR=2022CN784).

Questions, Recommendations, and Evidence Grade

The guidelines summarize 13 key clinical questions related to the status, diagnosis, treatment, and management of PN based on the results of literature analysis and expert opinions. The Grading of Recommendations Assessment,Development and Evaluation(GRADE) approach was used to classify the quality of evidence into four levels and the strength of recommendation into two levels. Recom-mendations were finally formulated in combination with expert opinions and experience. ${}^{[6]}$

Clinical question 1: What are the epidemiological profile and disease burden of PN?

Recommendations:

- The incidence of PN increases with age, and intractable pruritus seriously affects the quality of life of patients.[GRADE: 1B][Agreement: 95%;Indetermination: 5%]

- PN has a severe direct and indirect disease bur-den.[GRADE: 1B][Agreement: 100%]

Clinical question 2: What is the primary pathogenesis of PN?

Recommendations:

- The specific pathogenesis of PN remains unclear.The role of immune and neurological factors in its development has attracted increasing attention,and these factors have become potential thera-peutic targets.[GRADE: 2B][Agreement: 100%]

Clinical question 3: What diagnostic criteria are recommended for PN?

Recommendations:

- The diagnosis of PN requires a complete medical history, thorough physical examination, and labo-ratory tests.[GRADE: 1A][Agreement: 100%]

\blacksquare$ Attention should be given to the following four points: the presence of multiple localized or generalized nodular lesions; persistent pruritus for more than 6 weeks; a history of or clinical evidence of long-term scratching behavior; and the exclusion of other clinically similar diseases.[GRADE: 1B][Agreement: 100%]

- Accurate and early diagnosis is vital for optimizing disease management and scar prevention.[GRADE:GPS][Agreement: 95%; Disagreement: 5%]

Clinical question 4: Which diseases should PN be differentiated from?

Recommendations:

- PN needs to be differentiated from many other diseases, with purritus as the main manifestation.[GRADE: 2B][Agreement: 100%]

- The differential diagnosis requires a combination of medical history, lesion features, and, when necessary, skin biopsy or dermoscopy.[GRADE: 2C][Agreement: 100%]

Clinical question 5: How to grade the severity of the disease and evaluate treatment efficacy?

Recommendations:

- The severity of the disease should be evaluated by combining the number of nodules, the severity of puritus, the condition of the skin lesions, and the impact of the disease on quality of life.[GRADE:1B][Agreement: 100%]

- The severity of pruritus should be rated by the Worst Itch Numeric Rating Scale, skin lesions should be rated by the Investigator Global Assess-ment for Prurigo Nodularis Stage and Prurigo Activity Score, and skin-related quality of life should be rated by the Dermatology Life Quality Index.[GRADE: 2B][Agreement: 100%]

Clinical question 6: What are the treatment principles of PN?

Recommendations:

- Long-term or complete control of the disease can be achieved by controlling pruritus, restoring skin lesions, and fully considering the treatment of comorbidities. The treatment regimen should be selected after thoroughly weighing the pros and cons regarding drug safety and improvement in quality of life.[GRADE: GPS][Agreement: 100%]

Clinical question 7: How to provide health education for patients with PN, and what precautions should be taken in life?

Recommendations:

- The management of primary diseases and comor-bidities(including mental and psychological problems) should be strengthened. [GRADE:GPS][Agreement: 100%]

- Health education on wearing, bathing, and skin care should be strengthened for patients.[GRADE: GPS][Agreement: 95%; Indetermina-tion: 5%]

Chinese Medical Journal 2025;XX(XX)

www.cmj.org

Clinical question 8: How to treat PN with or without AD?

Recommendations:

■ For patients with concomitant AD, treatment regimens that can address both diseases simulta-neously should be given priority. [GRADE: GPS][Agreement: 95%; Indetermination: 5%]

For patients with nonatopic diseases related to PN, the interaction of different treatment regimens should be fully evaluated, the control of underlying diseases should be strengthened,and multidisciplinary consultation should be coordinated when necessary.[GRADE: GPS][Agreement: 95%; Indetermination: 5%]

Clinical question 9: How to apply glucocorticoids?

Recommendations:

For patients with mild PN, topical glucocorticoids are recommended.[GRADE: 2C][Agreement:100%]

For patients with fewer than 20 hypertrophic skin lesions, intralesional injection is recommended.[GRADE: 2C][Agreement: 100%]

\Box \quad Long-term systemic use of glucocorticoids is not recommended.[GRADE: 1B][Agreement: 100%]

Clinical question 10: How to apply topical calcineurin inhibitors and other topical agents?

Recommendations:

- Topical calcineurin inhibitors can be used in patients with PN, especially those requiring long-term maintenance therapy or intolerant to topical glucocorticoids.[GRADE: 2C][Agrade: 95%;Indetermination: 5%]

Clinical question 11: How to apply biological agents?

Recommendations:

\Box Interleukin-4 receptor blockers, such as dupi-lumab, are recommended as the first-line systemic treatment for patients with PN that cannot be controlled by local therapy.[GRADE: 1A][Agree-ment: 95%; Indetermination: 5%]

Clinical question 12: How to apply Janus kinase inhibitors?

Recommendations:

- Observational studies have suggested that Janus kinase inhibitors can improve puritus and dis-ease severity in the treatment of PN; however,high-quality research evidence is still lacking.

[GRADE: D][Agreement: 95%; Indetermination:5%]

Clinical question 13: How to apply antihistamines?

Recommendations:

$\boxed{The\,clinical\,effacy\,of\,antihistamines\,for\,PN\,has}$ not been fully validated and may require high doses or combinations with other treatments. The limited use of antihistamines is recommended in the early stage of PN.[GRADE: 2C][Agreement:95\%; Indetermination: 5\%]

In summary, PN is a chronic pruritic disease that seriously affects the quality of life of patients. It can occur alone or be associated with other underlying medical conditions, includ-ing skin diseases, psychological disorders, and systemic disorders. Intractable pruritus and the chronic recurrent course of the disease seriously affect the lives of patients,and the treatment of PN has long been a clinical challenge.With a deeper understanding of the etiology and mechanism of PN, several randomized controlled trials using targeted therapies have been conducted, and dupilumab has emerged as an indication drug by the Food and Drug Administration.Undoubtedly, there is still a need to develop more targeted and individualized treatment regimens for PN to meet the diverse treatment needs of patients.

Funding

This work was partly supported by a grant from the National Key Research and Development Programme of China(No.2023YFC2508200).

References

1. Zhang Li XL, Qian A, Hao G, Xinghua G. Pathogenesis and treatment of purorigo nodularis(in Chinese). Chin J Allergy Clin Immunol 2023;17:162-168.

2. Zhong Ting L.O. Research progress in the pathogenesis of puroriga nodularis(in Chinese). Chin J Dermatovenereol 2020;34:1453-1455,1459.doi:10.113735/j.cjvd.1001-7089.201912068.

3. Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Molla-nazar N, Yosipovitch G. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel con-sensus. J Am Acad Dermatol 2021;84:747-760. doi: 10.1016/j.jaad.2020.07.025.

4.Satoh T, Yokozeki H, Murota H, Tokura Y, Kabashima K, Taka-mori K, et al. 2020 guidelines for the diagnosis and treatment of prurigol. J Dermatol 2021;48:e414-e431. doi: 10.1111/1346-8138.16067.

5.Weisshaar E, Szepietowski JC, Dalgard FJ, Carovich S, Gieler U, Giménez-Arnau AM, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol 2019;99:469-506. doi:10.2340/00015555-3164.

6.Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek, J et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-394.doi: 10.1016/j.jclinepi.2010.04.026.